Napo pharmaceuticals, a jaguar health family company, accepted to present results of its pivotal phase 3 ontarget study for preventive treatment of cancer therapy-related diarrhea december 7th at the san antonio breast cancer symposium

Top line results of this pivotal trial expected before thanksgiving more than 1 million cancer patients in the us receive chemotherapy or radiation each year, according to the cdc, and cancer patients with diarrhea are 40% more likely to discontinue their targeted therapy san francisco, ca / accesswire / october 25, 2023 / napo pharmaceuticals (napo), a jaguar health, inc. (nasdaq:jagx) family company, today announced that on december 7, 2023, the company will present results from its pivotal phase 3 ontarget study of napo's plant-based prescription drug crofelemer under investigation for the prophylaxis (prevention) of diarrhea associated with targeted cancer therapies used to treat solid tumors at the san antonio breast cancer symposium (sabcs). napo expects to announce top line results of the trial by the thanksgiving holiday.
JAGX Ratings Summary
Quant
JAGX Quant Ranking
Sector
Industry
Quant Rating
Quant Score